europeanpharmaceuticalreviewMarch 27, 2020
Tag: hydroxychloroquine , India , COVID-19
India’s commerce department has announced that it will cease exports of Ipca (hydroxychloroquine), to the US soon after the Food and Drug Administration (FDA) lifted an import ban on the drug to aid the fight against COVID-19.
Although President Donald Trump has highlighted that the medicine could work as a potential coronavirus treatment, India will no longer ship hydroxychloroquine, approved to treat malaria.
However, the Indian government has confirmed that hydroxychloroquine will be exported if orders were made or paid for before the current notice. According to the Indian Ministry of Commerce & Industry, the only exception to export hydroxychloroquine will be on humanitarian grounds, assessed on a "case-to-case" basis.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: